GlassScriptPhysician profile
Antoine J Harb
NPI 1609014695
$11,269.99
in general payments reported to CMS, 2019-2025
67 companies · $3,380 in 2025
The $3,380 reported for 2025 was more than what 76% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $525 · 2022: $1,597 · 2023: $2,100 · 2024: $3,668 · 2025: $3,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,035 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,035.01 |
| Education | $113.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,015.83 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $838.33 | 2022-2025 | Opdivo, Opdualag, Augtyro |
| Merck Sharp & Dohme LLC | $796.88 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $745.24 | 2022-2025 | Enhertu, Imfinzi, Calquence |
| Genzyme Corporation | $492.24 | 2021-2025 | |
| Daiichi Sankyo INC. | $484.00 | 2022-2025 | Enhertu, Injectafer, Datroway |
| Incyte Corporation | $468.12 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Celgene Corporation | $455.51 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Karyopharm Therapeutics INC. | $398.63 | 2021-2025 | Xpovio |
| Pfizer INC. | $362.63 | 2021-2025 | |
| Janssen Biotech, INC. | $324.21 | 2021-2025 | Tecvayli, Talvey, Erleada |
| Genentech USA, INC. | $301.36 | 2022-2025 | Polivy, Lunsumio, Columvi |
| Amgen INC. | $294.98 | 2021-2023 | Nplate, Xgeva, Vectibix |
| Glaxosmithkline, LLC. | $266.83 | 2021-2025 | Ojjaara |
| Tempus Ai, INC | $235.91 | 2024 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $229.63 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $220.45 | 2022-2025 | Fruzaqla, Iclusig, Alunbrig |
| Eisai INC. | $193.11 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $183.00 | 2022-2024 | |
| Kite Pharma, INC. | $180.59 | 2021-2025 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $151.27 | 2023-2025 | Libtayo |
| Alexion Pharmaceuticals, INC. | $146.85 | 2022-2024 | Ultomiris, Soliris |
| Genmab U.S., INC. | $146.46 | 2023-2025 | Epkinly |
| Astellas Pharma US INC | $125.68 | 2024-2025 | Vyloy, Xtandi, Xospata |
| Taiho Oncology, INC. | $123.96 | 2023-2025 | |
| Gilead Sciences, INC. | $114.69 | 2023-2025 | Trodelvy |
| Adaptive Biotechnologies Corporation | $114.18 | 2021 | |
| Abbvie INC. | $112.77 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $108.35 | 2022-2025 | |
| Sobi, INC | $108.24 | 2022-2025 | |
| Agios Pharmaceuticals, INC. | $101.07 | 2023-2025 | Pyrukynd |
| Rigel Pharmaceuticals, INC. | $89.35 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Adc Therapeutics America, INC. | $83.61 | 2021-2024 | |
| Stemline Therapeutics INC. | $82.85 | 2023-2025 | Orserdu |
| Apellis Pharmaceuticals, INC. | $80.99 | 2024-2025 | Empaveli |
| Deciphera Pharmaceuticals INC. | $79.19 | 2023-2024 | Qinlock, Tgct |
| Ipsen Biopharmaceuticals, INC | $74.00 | 2023-2025 | Onivyde, Somatuline Depot |
| Morphosys, US INC. | $73.51 | 2022-2024 | Monjuvi |
| Pharmaessentia USA Corporation | $72.72 | 2023-2025 | Besremi |
| Emd Serono, INC. | $63.32 | 2024-2025 | |
| Sandoz INC. | $56.31 | 2021 | |
| Azurity Pharmaceuticals, INC. | $48.69 | 2024-2025 | Danziten, Vivimusta |
| Array Biopharma INC | $43.69 | 2025 | Mektovi, Xalkori, Braftovi |
| Geron Corporation | $39.17 | 2025 | Rytelo |
| Jazz Pharmaceuticals INC. | $37.36 | 2024-2025 | |
| Pharmacosmos Therapeutics INC. | $34.97 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.08 | 2022 | |
| Mirati Therapeutics, INC. | $32.90 | 2023 | Krazati |
| Immunocore Limited | $32.66 | 2023 | Kimmtrak |
| Beone Medicines USA, INC. | $27.66 | 2025 | Tevimbra |
| Foundation Medicine, INC. | $26.41 | 2023 | |
| Sumitomo Pharma America, INC. | $26.37 | 2025 | Orgovyx |
| Cti Biopharma Corp. | $24.22 | 2022 | |
| Sirtex Medical INC | $21.40 | 2024 | Sir-Spheres Microspheres |
| Spectrum Pharmaceuticals INC. | $20.82 | 2024 | Rolvedon |
| Aveo Pharmaceuticals, INC. | $20.45 | 2025 | |
| Pharmacyclics LLC, An Abbvie Company | $20.34 | 2023 | Epkinly |
| Recordati_rare_diseases_inc. | $20.24 | 2023 | Sylvant |
| Dova Pharmaceuticals | $20.01 | 2021 | |
| Octapharma USA, INC. | $20.00 | 2024 | Panzyga |
| Puma Biotechnology, INC. | $19.63 | 2021 | |
| Springworks Therapeutics, INC. | $19.53 | 2024 | Ogsiveo |
| Amag Pharmaceuticals, INC. | $19.28 | 2021 | |
| Alnylam Pharmaceuticals INC. | $17.27 | 2022 | |
| Seagen INC. | $16.80 | 2023 | Adcetris |
| Exelixis INC. | $14.70 | 2024 | Cabometyx |
| Blueprint Medicines Corporation | $14.49 | 2024 | Ayvakit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antoine Harb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.